ALCAM (CD166) expression and serum levels in pancreatic cancer

Standard

ALCAM (CD166) expression and serum levels in pancreatic cancer. / Tachezy, Michael; Zander, Hilke; Marx, Andreas H; Stahl, Phillip R; Gebauer, Florian; Izbicki, Jakob R; Bockhorn, Maximilian.

In: PLOS ONE, Vol. 7, No. 6, 6, 01.01.2012, p. e39018.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Tachezy, M, Zander, H, Marx, AH, Stahl, PR, Gebauer, F, Izbicki, JR & Bockhorn, M 2012, 'ALCAM (CD166) expression and serum levels in pancreatic cancer', PLOS ONE, vol. 7, no. 6, 6, pp. e39018. https://doi.org/10.1371/journal.pone.0039018

APA

Tachezy, M., Zander, H., Marx, A. H., Stahl, P. R., Gebauer, F., Izbicki, J. R., & Bockhorn, M. (2012). ALCAM (CD166) expression and serum levels in pancreatic cancer. PLOS ONE, 7(6), e39018. [6]. https://doi.org/10.1371/journal.pone.0039018

Vancouver

Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLOS ONE. 2012 Jan 1;7(6):e39018. 6. https://doi.org/10.1371/journal.pone.0039018

Bibtex

@article{8132c479140d48169c137255b90f13b7,
title = "ALCAM (CD166) expression and serum levels in pancreatic cancer",
abstract = "BACKGROUND: This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule (ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could serve as a biomarker in the peripheral blood of PAC patients.MATERIAL AND METHODS: Tissue specimens and blood sera of patients with PAC (n = 264 and n = 116, respectively) and the sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, respectively).RESULTS: ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p = 0.261 and p = 0.660, respectively). S-ALCAM serum levels were significantly elevated compared to the sera of CP patients (p<0.001). The sensitivity of s-ALCAM in detecting PAC was 58.6% at a specificity of 73.9% (AUC = 0.69).CONCLUSIONS: ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further investigations are required.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Enzyme-Linked Immunosorbent Assay, Antigens, CD/*blood/*metabolism, Cell Adhesion Molecules, Neuronal/*blood/*metabolism, Fetal Proteins/*blood/*metabolism, Pancreatic Neoplasms/*blood/*metabolism, Pancreatitis, Chronic/blood/metabolism, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Enzyme-Linked Immunosorbent Assay, Antigens, CD/*blood/*metabolism, Cell Adhesion Molecules, Neuronal/*blood/*metabolism, Fetal Proteins/*blood/*metabolism, Pancreatic Neoplasms/*blood/*metabolism, Pancreatitis, Chronic/blood/metabolism",
author = "Michael Tachezy and Hilke Zander and Marx, {Andreas H} and Stahl, {Phillip R} and Florian Gebauer and Izbicki, {Jakob R} and Maximilian Bockhorn",
year = "2012",
month = jan,
day = "1",
doi = "10.1371/journal.pone.0039018",
language = "English",
volume = "7",
pages = "e39018",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

RIS

TY - JOUR

T1 - ALCAM (CD166) expression and serum levels in pancreatic cancer

AU - Tachezy, Michael

AU - Zander, Hilke

AU - Marx, Andreas H

AU - Stahl, Phillip R

AU - Gebauer, Florian

AU - Izbicki, Jakob R

AU - Bockhorn, Maximilian

PY - 2012/1/1

Y1 - 2012/1/1

N2 - BACKGROUND: This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule (ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could serve as a biomarker in the peripheral blood of PAC patients.MATERIAL AND METHODS: Tissue specimens and blood sera of patients with PAC (n = 264 and n = 116, respectively) and the sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, respectively).RESULTS: ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p = 0.261 and p = 0.660, respectively). S-ALCAM serum levels were significantly elevated compared to the sera of CP patients (p<0.001). The sensitivity of s-ALCAM in detecting PAC was 58.6% at a specificity of 73.9% (AUC = 0.69).CONCLUSIONS: ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further investigations are required.

AB - BACKGROUND: This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule (ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could serve as a biomarker in the peripheral blood of PAC patients.MATERIAL AND METHODS: Tissue specimens and blood sera of patients with PAC (n = 264 and n = 116, respectively) and the sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, respectively).RESULTS: ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p = 0.261 and p = 0.660, respectively). S-ALCAM serum levels were significantly elevated compared to the sera of CP patients (p<0.001). The sensitivity of s-ALCAM in detecting PAC was 58.6% at a specificity of 73.9% (AUC = 0.69).CONCLUSIONS: ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further investigations are required.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Enzyme-Linked Immunosorbent Assay

KW - Antigens, CD/blood/metabolism

KW - Cell Adhesion Molecules, Neuronal/blood/metabolism

KW - Fetal Proteins/blood/metabolism

KW - Pancreatic Neoplasms/blood/metabolism

KW - Pancreatitis, Chronic/blood/metabolism

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Enzyme-Linked Immunosorbent Assay

KW - Antigens, CD/blood/metabolism

KW - Cell Adhesion Molecules, Neuronal/blood/metabolism

KW - Fetal Proteins/blood/metabolism

KW - Pancreatic Neoplasms/blood/metabolism

KW - Pancreatitis, Chronic/blood/metabolism

U2 - 10.1371/journal.pone.0039018

DO - 10.1371/journal.pone.0039018

M3 - SCORING: Journal article

C2 - 22745698

VL - 7

SP - e39018

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 6

M1 - 6

ER -